GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Q

Qyuns Therapeutics Co 2509.HK · HKD

N/A · HKEX · 🇭🇰 Hong Kong

Compare

14.50

+1.19%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥915.7m

FY2021FY2025

Net income

CN¥356.8m

FY2021FY2025

Free cash flow

CN¥456.9m

FY2021FY2025

Shareholders' equity

CN¥808.8m

FY2021FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021
RevenueCN¥915.7mCN¥158.8mCN¥14.8mCN¥9.7mCN¥24.9m
Research and developmentCN¥278.7mCN¥334.3mCN¥364.4mCN¥270.7mCN¥176.9m
Operating incomeCN¥372.4m−CN¥342.3m−CN¥516.4m−CN¥324.2m−CN¥208.9m
Net incomeCN¥356.8m−CN¥335.6m−CN¥507.7m−CN¥298.2m−CN¥478.8m
Diluted earnings per share1.58-1.51-2.29-1.34-2.16

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Total assetsCN¥1.86bnCN¥983.9mCN¥795.6mCN¥1.16bnCN¥1.52bn
Cash and short-term investmentsCN¥1.21bnCN¥556.6mCN¥377.3mCN¥689.6mCN¥722.7m
Total liabilitiesCN¥1.07bnCN¥762.8mCN¥494.6mCN¥419.6mCN¥517.7m
DebtCN¥675.6mCN¥527.6mCN¥346.1mCN¥295.3mCN¥337.7m
Shareholders' equityCN¥808.8mCN¥229.0mCN¥324.5mCN¥641.7mCN¥780.9m
Shares outstanding225m222m222m222m222m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Cash from operationsCN¥465.8m−CN¥186.1m−CN¥300.7m−CN¥225.2m−CN¥142.8m
Capital spending−CN¥8.9m−CN¥1.2m−CN¥7.9m−CN¥26.5m−CN¥82.7m
Free cash flowCN¥456.9m−CN¥187.3m−CN¥308.6m−CN¥251.7m−CN¥225.5m

Financial ratios

Data as of 20 Oct 2026

FY2025FY2024FY2023FY2022FY2021
Operating margin40.7%-215.6%-3500.8%-3354.9%-840.0%
Net margin39.0%-211.3%-3442.1%-3086.2%-1925.3%
Return on equity44.1%-146.6%-172.3%-46.5%-61.3%
Return on assets19.1%-34.1%-63.8%-25.7%-38.5%
Free cash flow yield11.0%-5.2%-8.4%-6.3%—
Revenue growth395.0%976.5%52.7%-54.7%—
Earnings growth-191.3%-33.9%70.3%-27.5%—
Current ratio2.22x1.43x1.66x5.84x9.30x
Debt to equity0.84x2.30x1.17x0.46x0.43x
Equity ratio43.4%23.3%37.1%55.2%62.8%
Interest coverage14.81x-14.64x-30.70x-17.34x-10.05x
R&D as a share of sales30.4%210.5%2470.4%2662.1%711.4%
Buybacks as a share of market value-1.4%-0.0%0.0%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue355.9%——

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings10.4-4.2
Price to sales4.18.9

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.